Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT) (PROTECT)

Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)

The purpose of this study is to evaluate the long-term safety and efficacy of the Xact™ Rapid Exchange Carotid Stent System used in conjunction with the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5) and the Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3), in the treatment of atherosclerotic carotid artery disease in high-surgical risk subjects.

Study Overview

• Status: Completed
• Conditions: Carotid Artery Disease
• Intervention / Treatment: Device: Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)

• Study Type: Interventional
• Enrollment (Actual): 322
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Fremont, California, United States, 94538
      • Washington Hospital
    • Mountain View, California, United States, 94040
      • El Camino Hospital
    • Newport Beach, California, United States, 92663
      • Hoag Memorial Hospital Presbyterian
    • Stanford, California, United States, 94305
      • Stanford University Medical Center
  • Connecticut
    • Farmington, Connecticut, United States, 06030
      • University of Connecticut Health Center
  • Florida
    • Jacksonville, Florida, United States, 32216
      • Memorial Hospital Jacksonville
    • Lakeland, Florida, United States, 33805
      • Lakeland Regional Medical Center
    • Ocala, Florida, United States, 34475
      • Munroe Regional Medical Center
  • Hawaii
    • Honolulu, Hawaii, United States, 96819
      • Hawaii Permanente Medical Group-Kaiser Foundation Hospital
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University Memorial Hospital
    • Springfield, Illinois, United States, 62701
      • St. John's Hospital / Memorial Medical Center
  • Indiana
    • Fort Wayne, Indiana, United States, 46805
      • Parkview Hospital
    • Indianapolis, Indiana, United States, 46260
      • St. Vincent Hospital and Health Care Center
  • Louisiana
    • Houma, Louisiana, United States, 70360
      • Terrebonne General Medical Center
  • Maryland
    • Takoma Park, Maryland, United States, 20912
      • Washington Adventist Hospital
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
  • Michigan
    • Ann Arbor, Michigan, United States, 48106
      • St. Joseph Mercy Hospital
    • Flint, Michigan, United States, 48532
      • McLaren Regional Medical Center
    • Grand Blanc, Michigan, United States, 48439
      • Genesys Regional Medical Center
    • Royal Oak, Michigan, United States, 48073
      • William Beaumont Hospital
  • New Jersey
    • Camden, New Jersey, United States, 08103
      • Our Lady of Lourdes Medical Center
    • Newark, New Jersey, United States, 07102
      • St. Michael's Medical Center
  • New York
    • Buffalo, New York, United States, 14209
      • Millard Fillmore Hospital-Kaleida Health Systems
    • New York, New York, United States, 10021
      • Lenox Hill Hospital
  • North Carolina
    • Raleigh, North Carolina, United States, 27610
      • WakeMed Hospital
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health & Science University
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18105
      • LeHigh Valley Hospital
    • Harrisburg, Pennsylvania, United States, 17110
      • Pinnacle Health Hospital
    • Wyomissing, Pennsylvania, United States, 19610
      • St. Joseph's Medical Center
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Greenville Memorial Medical Center
  • Tennessee
    • Kingsport, Tennessee, United States, 37660
      • Holston Valley Medical Center
    • Knoxville, Tennessee, United States, 37934
      • Mercy Medical Center West / Baptist Hospital of East Tennessee
  • Texas
    • Austin, Texas, United States, 78756
      • Austin Heart P.A.
    • Dallas, Texas, United States, 75231
      • Presbyterian Heart Institute
    • Houston, Texas, United States, 77030
      • St. Luke's Episcopal Hospital
  • Virginia
    • Norfolk, Virginia, United States, 23507
      • Chesapeake General Hospital
    • Richmond, Virginia, United States, 23226
      • Bon Secours St. Mary's Hospital
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53215
      • St. Luke's Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria Subject must be ≥ 18 years of age.

Subject has the ability to cooperate with study procedures and agrees to return for all required follow-up visits, tests and exams.

Female subjects of childbearing potential must have a documented negative pregnancy test within 30 days prior to the index procedure.

Subjects taking warfarin may be included if their dosage is reduced before the index procedure to result in an INR of 1.5 or less. Warfarin may be restarted to therapeutic dose after the index procedure.

The subject must sign a written informed consent prior to the initiation of any study procedures, using a form that is approved by the Institutional Review Board (IRB) or Medical Ethics Committee (EC).

The life expectancy of the subject is at least two years.

The subject has a lesion located in the internal carotid artery (ICA); the carotid bifurcation may be involved.

The target lesion is intended to be treated with a single stent.

Target ICA vessel diameter must be visually estimated to be:

• ≥2.5 mm and ≤7.0 for the Emboshield Pro (Gen 5)
• ≥ 2.8 mm and ≤6.2 for the Emboshield (Gen 3)

And

• ≥4.0 mm and ≤9.0 mm for the Xact Stent treatment area.

The subject has a carotid artery stenosis determined by ultrasound or angiography (visual estimate) to be:

• ≥50% for symptomatic subjects

Or

• ≥80% for asymptomatic subjects

High-risk inclusion criteria for either anatomical or co-morbid risk factors are present. The subject must fulfill at least one of the criteria, Category I or II risk factors, listed below to meet the inclusion criteria.

Category I Anatomic Risk Factors

• Previous radiation treatment to the neck or radical neck dissection
• Target lesion is at or above the second vertebral body C2 (level of jaw)
• Inability to extend the head due to cervical arthritis or other cervical disorders
• Tracheostomy or tracheal stoma
• Laryngectomy
• Contralateral laryngeal nerve palsy
• Severe tandem lesions

Category II Co-morbid Risk Factors

• Previous CEA with significant restenosis (as defined for symptomatic or asymptomatic subjects)
• Total occlusion of the contralateral carotid artery
• Left ventricular ejection fraction < 35%
• Congestive Heart failure New York Heart Association (NYHA) Functional Class III or higher
• Dialysis dependent renal failure
• Canadian Cardiovascular Society Angina Classification III or higher or unstable angina

• Requires coronary artery bypass surgery, cardiac valve surgery, peripheral vascular surgery, or abdominal aortic aneurysm repair within 60 days

  •≥80 years of age

• Myocardial infarction within previous 6 weeks
• Abnormal stress test. Treadmill, thallium or dobutamine echo are acceptable. The stress tests should be sufficiently abnormal to place the subject at increased risk for CEA. This includes subjects with two or more proximal diseased coronary arteries of >70% stenosis that have not or cannot be revascularized or <30 days since revascularization.
• Severe pulmonary disease, including at least one of the following: requires chronic O2 therapy; resting PO2 ≤60 mm Hg, Hematocrit ≥50%, FEV₁ or DLCO ≤50% of normal.

Exclusion Criteria

• The subject is participating in another investigational trial that would interfere with the conduct or result of this study.
• The subject has dementia or a neurological illness that may confound the neurological evaluation.
• Total occlusion of the target vessel.
• There is an existing, previously placed stent in the target artery.
• The subject has a known life-threatening allergy to the contrast media that cannot be treated.
• Subject has history of intolerance or allergic reaction to any of the study medications including aspirin, Clopidogrel bisulfate (Plavix®) or Ticlopidine (Ticlid®), heparin or Bivalirudin (Angiomax™). Subjects must be able to tolerate a combination of aspirin and Clopidogrel or aspirin and Ticlopidine.
• The subject has a GI bleed that would interfere with antiplatelet therapy.
• The subject has known cardiac sources of emboli, including but not limited to current or past history of paroxysmal or sustained atrial fibrillation (treated or untreated), valve replacement, etc.
• Subject has Hemoglobin (Hgb) less than 8 gm/dL (unless on dialysis), platelet count <50,000/mm3, or known heparin associated thrombocytopenia.
• The subject has a history of bleeding diathesis or coagulopathy including thrombocytopenia or an inability to receive heparin or Bivalirudin (Angiomax™) in amounts sufficient to maintain an ACT of >250, or will refuse blood transfusion.
• The subject has atherosclerotic disease involving adjoining vessels that precludes safe placement of the guiding catheter or sheath.
• The subject has other abnormal angiographic findings that indicate the subject is at risk for a stroke due to a problem other than that of the target lesion, such as: ipsilateral arterial stenosis greater in severity than the target lesion, cerebral aneurysm, or arteriovenous malformation of the cerebral vasculature.
• There is evidence of a carotid artery dissection prior to the initiation of the index procedure.
• There is an angiographically visible thrombus.
• There is any condition that precludes proper angiographic assessment, placement of the cerebral protective system or makes percutaneous arterial access unsafe, e.g. morbid obesity, sustained systolic blood pressure >180 mm Hg, tortuosity, occlusive disease, vessel anatomy, or aortic arch anatomy.
• Occlusion (TIMI 0 flow), or string sign of the ipsilateral common or internal carotid artery.
• There is evidence of bilateral carotid stenosis that would require intervention within 30 days of the index procedure.
• There is evidence of a stroke within the previous 30 days of the index procedure.
• There is a planned treatment of a non-target lesion within 30 days post-index procedure.
• There is a history of intracranial hemorrhage within the previous 3 months, including hemorrhagic transformation of an ischemic stroke.
• There is a history of an ipsilateral stroke with fluctuating neurologic symptoms within one year of the index procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kaplan-Meier Estimate of Freedom From the Composite of Any Death, Stroke and MI During the 30 Day Post Procedural Period (DSMI), Plus Fatal and Non-fatal Ipsilateral Stroke From 31-365 Days and Annually Thereafter for a Total of 3 Years.	Freedom from DSMI to 30 days or ipsilateral stroke from 31 days to 3 years. KM event free (%) curve.	3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acute Device Success	Defined by the attainment of <50% residual stenosis covering an area no longer than the original lesion treated with the stent.	Post-procedure
Procedural Success	Defined as the attainment of less than 50% residual stenosis (per angiographic core lab) of the target lesion and the absence of DSMI at 30 days post-index procedure.	30 Days
Composite of Any Transient Ischemic Attack (TIA) and Amaurosis Fugax	Includes only each subject's first occurrence of each event.	≤30 days
Kapan-Meier Estimate of Freedom From Clinically Driven Target Lesion Revascularization Through Three Years.		3 years

Collaborators and Investigators

• Sponsor: Abbott Medical Devices
• Investigators: Study Chair: Seemant Chaturvedi, MD, Wayne State University Stroke Program; Study Chair: Jon Matsumura, MD, University of Wisconsin, Madison

Publications and helpful links

Helpful Links

• Results of carotid artery stenting with distal embolic protection with improved systems: Protected Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy (PROTECT) trial.

Study record dates

Study Major Dates

• Study Start: November 1, 2006
• Primary Completion (ACTUAL): June 1, 2011
• Study Completion (ACTUAL): October 1, 2011

Study Registration Dates

• First Submitted: November 20, 2006
• First Submitted That Met QC Criteria: November 21, 2006
• First Posted (ESTIMATE): November 22, 2006

Study Record Updates

• Last Update Posted (ESTIMATE): June 20, 2012
• Last Update Submitted That Met QC Criteria: May 17, 2012
• Last Verified: May 1, 2012

More Information

Terms related to this study

• Keywords: Stent; Carotid; Disease; Artery; PROTECT; XACT; EMBOSHIELD
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Carotid Artery Diseases
• Other Study ID Numbers: 640-0071